NadAΔ351–405 and Its Role in Activating Human Monocytes
Author Information
Author(s): Cecchini Paola, Tavano Regina, Polverino de Laureto Patrizia, Franzoso Susanna, Mazzon Cristina, Montanari Paolo, Papini Emanuele
Primary Institution: Centro Ricerche Interdipartimentale Biotecnologie Innovative (C.R.I.B.I.), University of Padova, Padova, Italy
Hypothesis
How does the recombinant form of NadAΔ351–405 interact with human monocytes to stimulate immune responses?
Conclusion
The study demonstrates that NadAΔ351–405 activates human monocytes through a mechanism involving hsp90 and TLR4.
Supporting Evidence
- NadAΔ351–405 binds to hsp90 on the surface of human monocytes.
- Pre-incubation with NadAΔ351–405 inhibits the binding of anti-hsp90 antibodies.
- Polymixin B interferes with the NadAΔ351–405/hsp90 interaction but does not affect monocyte binding.
- Co-stimulation with anti-hsp90 antibodies enhances cytokine secretion from monocytes.
Takeaway
NadAΔ351–405 is a part of a potential vaccine that helps our immune cells, called monocytes, to fight infections by binding to a protein on their surface.
Methodology
The study involved binding assays, flow cytometry, and cytokine secretion analysis to investigate the interaction between NadAΔ351–405 and human monocytes.
Potential Biases
Potential bias due to the use of a single recombinant protein and specific antibodies in the experiments.
Limitations
The study does not address the long-term effects of NadAΔ351–405 on immune responses or its efficacy in vivo.
Participant Demographics
Human monocytes derived from buffy coats of healthy blood donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website